The activity of flavone acetic acid (NSC 347512) on human colon cancer cells in vitro B. DrewinkoL. -Y. Yang Preclinical Studies Pages: 289 - 293
Activity of tricyclic nucleoside 5′-phosphate in model systems of human ovarian cancer Brent C. BehrensThomas C. HamiltonRobert F. Ozols Preclinical Studies Pages: 295 - 304
Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells Robert T. DorrJames D. LiddilMichelle J. Soble Preclinical Studies Pages: 305 - 313
Cytotoxicity of combinations of prostaglandin D2 (PGD2) and antitumor drugs for B16 melanoma cells in culture Bijoy K. BhuyanGloria J. BadinerRobin Chase Preclinical Studies Pages: 315 - 323
Role of metabolism in effects of diflubenzuron on growth of B16 melanomas in mice Vernon K. JenkinsRobert R. PerryKirk Ives Preclinical Studies Pages: 325 - 335
Heterogeneous survival responses of human gastric cancer clones to αDifluoromethylornithine in vitro S. C. BarrancoP. J. FordC. M. Townsend Jr Preclinical Studies Pages: 337 - 345
Cell cycle kinetics responses of human stomach cancer cells to reduction in polyamine levels by treatment with αDifluoromethylornithine in vitro S. C. BarrancoP. J. FordC. M. Townsend Jr Preclinical Studies Pages: 347 - 357
Spirogermanium — A novel antitumour agent expressing a lack of cross-resistance in vitro with a range of ‘standard’ antitumour drugs Bridget T. HillR. D. H. Whelan Preclinical Studies Pages: 359 - 365
Sodium azide is less suitable as a positive control of drug-induced lethality for in vitro clonogenic assays Peter LelieveldMatti S. AaproKor J. van den Berg Preclinical Studies Pages: 367 - 371
Short communication: Cause and prevention of mafosfamide-induced venous pain Peter HilgardJörg Pohl Preclinical Studies Pages: 373 - 376
Recombinant gamma interferon in advanced breast cancer: A phase II trial Hyman B. MussMary CaponeraRobert L. Capizzi Clinical Studies Pages: 377 - 381
Phase II study of spirogermanium in patients with advanced colorectal carcinoma Jaffer A. AjaniJack S. FaintuchIrwin H. Krakoff Clinical Studies Pages: 383 - 385
Clinical pharmacology of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193) Robert M. GreenDavid J. StewartJean A. Maroun Clinical Studies Pages: 387 - 394